WO2015171960A1 - Methods and compositions comprising 10-hydroxy-2-decenoic acid - Google Patents

Methods and compositions comprising 10-hydroxy-2-decenoic acid Download PDF

Info

Publication number
WO2015171960A1
WO2015171960A1 PCT/US2015/029790 US2015029790W WO2015171960A1 WO 2015171960 A1 WO2015171960 A1 WO 2015171960A1 US 2015029790 W US2015029790 W US 2015029790W WO 2015171960 A1 WO2015171960 A1 WO 2015171960A1
Authority
WO
WIPO (PCT)
Prior art keywords
day
amount
composition
hydroxy
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/029790
Other languages
English (en)
French (fr)
Inventor
Michael Weiser
Christopher BUTT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to JP2016566933A priority Critical patent/JP6819957B2/ja
Priority to BR112016026143A priority patent/BR112016026143A2/pt
Priority to KR1020167034149A priority patent/KR102399290B1/ko
Priority to EP15789367.8A priority patent/EP3139741A4/en
Priority to CN201580036769.1A priority patent/CN106470547B/zh
Priority to US15/309,470 priority patent/US10004711B2/en
Publication of WO2015171960A1 publication Critical patent/WO2015171960A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • compositions for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising 10-Hydroxy-2-decenoic acid and at least one polyunsaturated fatty acid.
  • methods for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising administration of 10-Hydroxy-2-decenoic acid, wherein such method may further comprise administration of at least one polyunsaturated fatty acid.
  • Queen bee acid (10-hydroxy-2-decenoic acid) is the predominant fatty acid constituent of royal jelly.
  • Royal jelly is harvested from a select population of cells that specifically support the growth and development of queen bee larvae and is provided to the queen bee by the drones. Royal jelly is believed to play a role in the enhanced size, fertility and lifespan of queen bees. It is believed that queen bee acid (10-hydroxy-2-decenoic acid) is one of the principal active components of royal jelly.
  • Queen bee acid inhibits histone deacetylases and is now recognized as the epigenetic switch for the queen bee larvae phenotype (Spannhoff et al., Histone Deacetylase Inhibitor Activity in Royal Jelly Might Facilitate Caste Switching in Bees, EMBO Reports, Vol. 12, No. 3, 2011).
  • Other in vitro effects of queen bee acid include antitumor activity (Townsend et al., Studies on the in vitro Antitumor Activity of Fatty Acids: I.
  • queen bee acid (10-hydroxy-decenoic acid) has an effect in the treatment of anxiety, inflammatory conditions and fertility-related disorders, and may increase cognitive performance and help manage weight, wherein managing weight is maintaining weight in a subject having a diseased state, or weight loss, particularly where such weight loss is due to age or stress.
  • the queen bee acid can be in the form of a free fatty acid, salt, fatty acid ester
  • the queen bee acid is in the free fatty acid or salt form.
  • compositions for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising 10-Hydroxy-2-decenoic acid and at least one polyunsaturated fatty acid.
  • methods for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising administration of 10-Hydroxy-2-decenoic acid, wherein such method may further comprise administration of at least one polyunsaturated fatty acid.
  • the composition comprises 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA).
  • PUFA polyunsaturated fatty acid
  • the composition comprises a PUFA that is an omega-3 fatty acid. More preferably, the composition comprises an omega-3 fatty acid with 20 or 22 carbon atoms. Most preferably, the composition comprises a PUFA that is an omega-3 fatty acid and is all- cz ' s-docosa-4,7, 10,13, 16, 19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • the methods disclosed herein comprise administration of
  • 10-Hydroxy-2-decenoic acid or a derivative thereof for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight.
  • the methods further comprise administration of at least one polyunsaturated fatty acid (PUFA).
  • PUFA polyunsaturated fatty acid
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cz ' s-docosa-4,7, 10,13, 16, 19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • compositions for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising 10-Hydroxy-2-decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA).
  • methods for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising administration of 10- Hydroxy-2-decenoic acid or a derivative thereof, and further comprising administration of at least one polyunsaturated fatty acid.
  • compositions comprising about 0.2 mg to about 5000 mg 10-Hydroxy-2-decenoic acid and about 100 mg to about 4000 mg DHA in the form preferably of one or more capsules.
  • the respective amounts are about 12 mg to about 300 mg 10-Hydroxy-2-decenoic acid mg and about 100 mg to about 1500 mg DHA.
  • the 10-Hydroxy-2-decenoic acid may be provided in a form of a free acid or an ester.
  • the free acid preferably is provided separate from DHA.
  • the QBA-ester may be combined with DHA in one dosage form.
  • terapéuticaally-effective amount refers to that amount of a compound sufficient to modulate one or more of the symptoms of the condition or disease being treated.
  • a “therapeutically-effect amount” and/or dosage range for compounds used in the method of treatment of the invention may be determined by one of ordinary skill in the art via known criteria including age, weight, and response of the individual patient, and interpreted within the context of the disease being treated and/or prevented.
  • Fatty acids are classified based on the length and saturation characteristics of the carbon chain.
  • Fatty acids present in a microbial oil can have from 4 to 28 carbon atoms and are termed short chain, medium chain, or long chain fatty acids based on the number of carbons present in the chain.
  • Fatty acids are termed saturated fatty acids when no double bonds are present between the carbon atoms, and are termed unsaturated fatty acids when double bonds are present.
  • Unsaturated long chain fatty acids are monounsaturated when only one double bond is present and are polyunsaturated when more than one double bond is present.
  • Polyunsaturated fatty acids are classified based on the position of the first double bond from the methyl end of the fatty acid; omega-3 (n-3) fatty acids contain a first double bond at the third carbon, while omega-6 (n-6) fatty acids contain a first double bond at the sixth carbon.
  • DHA docosahexaenoic acid
  • LC-PUFA omega-3 long chain polyunsaturated fatty acid
  • the PUFA is selected from an omega-3 fatty acid, an omega-6 fatty acid, and mixtures thereof. In another embodiment, the PUFA is selected from long-chain polyunsaturated fatty acids (LC -PUFAs). In another embodiment, the LC PUFA has 20 carbon atoms or more, preferably C20 or C22 carbon atoms.
  • the PUFA is selected from docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DP A), arachidonic acid (ARA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), stearidonic acid (SDA), and mixtures thereof.
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • DP A docosapentaenoic acid
  • ARA arachidonic acid
  • GLA gamma-linolenic acid
  • DGLA dihomo-gamma-linolenic acid
  • SDA stearidonic acid
  • the PUFA is selected from DHA, ARA, and mixtures thereof.
  • the PUFA is ARA.
  • the PUFA is DHA.
  • the PUFAs can be in the form of a free fatty acid, salt, fatty acid ester (e.g., methyl or ethyl ester), monoacylglycerol (MAG), diacylglycerol (DAG), triacylglycerol (TAG), and/or phospholipid (PL), or mixtures thereof.
  • fatty acid ester e.g., methyl or ethyl ester
  • MAG monoacylglycerol
  • DAG diacylglycerol
  • TAG triacylglycerol
  • PL phospholipid
  • the PUFA is in the ethyl ester or glyceryl ester form, like the TAG form.
  • any source of PUFA can be used in the compositions and methods of the invention, including, for example, animal, plant and microbial sources.
  • Preferred polyunsaturated fatty acid (PUFA) sources can be any source of PUFA that are suitable for use in the present invention.
  • animal sources include aquatic animals (e.g., fish, marine mammals, crustaceans, rotifers, etc.).
  • plant sources include microalgae, flaxseeds, rapeseeds, corn, evening primrose and borage.
  • microorganisms include microalgae, protists, bacteria and fungi (including yeast).
  • the use of a microorganism source, such as microalgae can provide organoleptic advantages.
  • the polyunsaturated fatty acid source comprises microalgae or microalgal oils.
  • the microorganisms are cultured in a fermentation medium in a fermenter.
  • the microorganisms can be cultured photosynthetically in a photobioreactor or pond.
  • the microorganisms are lipid-rich microorganisms, more preferably, the microorganism are selected from the group consisting of microalgae, bacteria, fungi and protists, more preferably, the microorganisms are selected from the group consisting of dioflagellates, yeast and fungi of the genus Mortierella.
  • the microorganisms comprise microorganisms of the genus Crypthecodinium and order Thraustochytriales and filamentous fungi of the genus Mortierella, and more preferably, microorganisms are selected from the genus Thraustochytrium, Schizocythrium, or mixtures thereof.
  • the polyunsaturated fatty acids that are used in the compositions described herein are in a variety of forms, for example, such forms include, but are not limited to, a highly purified algal oil comprising a PUFA, a plant oil comprising the PUFA, triglyceride oil comprising the PUFA, phospholipid comprising the PUFA, a combination of protein and phospholipids comprising the PUFA, dried marine microalgae comprising the PUFA, sphingolipids comprising the PUFA, esters of the PUFA, free fatty acid, a conjugate of the PUFA with another bioactive molecule, and conjugates thereof.
  • compositions for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight comprising 10-Hydroxy-2-decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA).
  • PUFA polyunsaturated fatty acid
  • One embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating anxiety.
  • PUFA polyunsaturated fatty acid
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cz ' s-docosa-4,7, 10, 13,16,19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating anxiety wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for treating anxiety wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating anxiety wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for treating anxiety wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating an inflammatory condition.
  • PUFA polyunsaturated fatty acid
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cz ' s-docosa-4,7,10, 13,16, 19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating an inflammatory condition wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for treating an inflammatory condition wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating an inflammatory condition wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for treating an inflammatory condition wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • the inflammatory condition comprises a gastrointestinal disorder.
  • the inflammatory condition is colitis.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for increasing cognitive performance.
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cz ' s-docosa-4,7,10, 13,16, 19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for increasing cognitive performance wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for increasing cognitive performance wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for increasing cognitive performance wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for increasing cognitive performance wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • the increasing cognitive performance comprises increased speed of learning, improved memory retention, and combinations thereof.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for managing weight.
  • managing weight is managing weight in a subject having a diseased state.
  • managing weight is weight loss.
  • the weight loss is associated with aging.
  • the weight loss is associated with stress.
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cz ' s-docosa-4,7,10, 13,16, 19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for managing weight wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • managing weight is managing weight in a subject having a diseased state.
  • managing weight is weight loss.
  • the weight loss is associated with aging.
  • the weight loss is associated with stress.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for managing weight wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • managing weight is managing weight in a subject having a diseased state.
  • managing weight is weight loss.
  • the weight loss is associated with aging.
  • the weight loss is associated with stress.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for managing weight wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • managing weight is managing weight in a subject having a diseased state.
  • managing weight is weight loss.
  • the weight loss is associated with aging.
  • the weight loss is associated with stress.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for managing weight wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • managing weight is managing weight in a subject having a diseased state.
  • managing weight is weight loss.
  • the weight loss is associated with aging.
  • the weight loss is associated with stress.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating fertility-related disorders.
  • PUFA polyunsaturated fatty acid
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cz ' s-docosa-4,7,10, 13,16, 19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating fertility-related disorders wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for treating fertility-related disorders wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 4000 mg/day.
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and at least one polyunsaturated fatty acid (PUFA) for treating fertility-related disorders wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the PUFA is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • PUFA polyunsaturated fatty acid
  • Another embodiment is directed to a composition comprising 10-Hydroxy-2- decenoic acid or a derivative thereof, and docosahexaenoic acid for treating fertility-related disorders wherein the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day and the docosahexaenoic acid is administered in an amount of about 100 mg/day to about 1500 mg/day.
  • the fertility-related disorder comprises idiosyncratic infertility, polycystic ovarian syndrome, and primary ovarian insufficiency.
  • the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day, in an amount of about 0.4 mg/day to about 4500 mg/day, in an amount of about 0.6 mg/day to about 4000 mg/day, in an amount of about 0.8 mg/day to about 3500 mg/day, in an amount of about 1 mg/day to about 3000 mg/day, in an amount of about 2 mg/day to about 2500 mg/day, in an amount of about 3 mg/day to about 2000 mg/day, in an amount of about 4 mg/day to about 1500 mg/day, in an amount of about 5 mg/day to about 1000 mg/day, in an amount of about 6 mg/day to about 900 mg/day, in an amount of about 7 mg/day to about 800 mg/day, in an amount of about 8 mg/day to about 700 mg/day, in an amount of about 9 mg/day to about 600 mg/day, in an amount of about 10 mg/
  • the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day, in an amount of about 125 mg/day to about 4500 mg/day, in an amount of about 150 mg/day to about 4000 mg/day, in an amount of about 175 mg/day to about 3500 mg/day, in an amount of about 200 mg/day to about 3000 mg/day, in an amount of about 225 mg/day to about 2500 mg/day, in an amount of about 250 mg/day to about 2000 mg/day, in an amount of about 275 mg/day to about 1500 mg/day, in an amount of about 300 mg/day to about 1000 mg/day, in an amount of about 325 mg/day to about 900 mg/day, in an amount of about 100 mg/day, in an amount of about 125 mg/day, in an amount of about 150 mg/day, in an amount of about 175 mg/day, in an amount of about 200 mg/day, in an amount of about 225 mg/day, in an amount of about
  • the composition comprising 10-Hydroxy-2-decenoic acid or a derivative thereof and at least one polyunsaturated fatty acid further comprises a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier is selected from a solid carrier and a liquid carrier.
  • Solid carriers include, but are not limited to, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents.
  • a solid carrier can also be an encapsulating material.
  • Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid dosage forms include, but are not limited to, for example, solutions, suspensions, and emulsions.
  • Disclosed herein are methods for treating anxiety, inflammatory conditions and fertility-related disorders, and for increasing cognitive performance and managing weight, wherein such methods comprise administration of 10-Hydroxy-2-decenoic acid or a derivate thereof.
  • the methods may further comprise administration of at least one polyunsaturated fatty acid.
  • One embodiment is directed to a method of treating anxiety in a subject in need thereof, comprising administering a therapeutically effective amount of 10-Hydroxy-2- decenoic acid or a derivative thereof.
  • Another embodiment is directed to use of 10-Hydroxy- 2-decenoic acid or a derivative thereof for treating anxiety.
  • Another embodiment is directed to a method of treating an inflammatory condition in a subject in need thereof, comprising administering a therapeutically effective amount of 10-Hydroxy-2-decenoic acid or a derivative thereof.
  • Another embodiment is directed to use of 10-Hydroxy-2-decenoic acid or a derivative thereof for treating an inflammatory condition.
  • the inflammatory condition comprises a gastrointestinal disorder. More preferably, the inflammatory condition is colitis.
  • Another embodiment is directed to a method of increasing cognitive performance in a subject, comprising administering a therapeutically effective amount of 10- Hydroxy-2-decenoic acid or a derivative thereof.
  • Another embodiment is directed to use of 10-Hydroxy-2-decenoic acid or a derivative thereof for increasing cognitive performance.
  • the increasing cognitive performance comprises increased speed of learning, improved memory retention, and combinations thereof.
  • Another embodiment is directed to a method for managing weight in a subject in need thereof, comprising administering a therapeutically effective amount of 10-Hydroxy- 2-decenoic acid or a derivative thereof.
  • the managing weight is managing weight loss.
  • Another embodiment is directed to use of 10-Hydroxy-2-decenoic acid or a derivative thereof for managing weight.
  • managing weight is managing weight in a subject having a diseased state.
  • managing weight is weight loss.
  • the weight loss is associated with aging.
  • the weight loss is associated with stress.
  • Another embodiment is directed to a method for treating fertility-related disorders in a subject in need thereof, comprising administering a therapeutically effective amount of 10-Hydroxy-2-decenoic acid or a derivative thereof.
  • Another embodiment is directed to use of 10-Hydroxy-2-decenoic acid or a derivative thereof for treating fertility- related disorders.
  • the fertility-related disorder comprises idiosyncratic infertility, polycystic ovarian syndrome, and primary ovarian insufficiency.
  • the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day, in an amount of about 0.4 mg/day to about 4500 mg/day, in an amount of about 0.6 mg/day to about 4000 mg/day, in an amount of about 0.8 mg/day to about 3500 mg/day, in an amount of about 1 mg/day to about 3000 mg/day, in an amount of about 2 mg/day to about 2500 mg/day, in an amount of about 3 mg/day to about 2000 mg/day, in an amount of about 4 mg/day to about 1500 mg/day, in an amount of about 5 mg/day to about 1000 mg/day, in an amount of about 6 mg/day to about 900 mg/day, in an amount of about 7 mg/day to about 800 mg/day, in an amount of about 8 mg/day to about 7000 mg/day, in an amount of about 9 mg/day to about 600 mg/day, in an amount of about 10 mg
  • the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 0.2 mg/day to about 5000 mg/day. More preferably, the 10-Hydroxy-2-decenoic acid or derivative thereof is administered in an amount of about 12 mg/day to about 300 mg/day.
  • the methods disclosed herein may further comprise administering a therapeutically effective amount of at least one polyunsaturated fatty acid (PUFA).
  • PUFA polyunsaturated fatty acid
  • the PUFA is an omega-3 fatty acid. More preferably, the PUFA is a//-cw-docosa- 4,7, 10, 13, 16,19-hexaenoic acid, also known as docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • the PUFA is administered in an amount of about 100 mg/day to about 4000 mg/day, in an amount of about 125 mg/day to about 4500 mg/day, in an amount of about 150 mg/day to about 4000 mg/day, in an amount of about 175 mg/day to about 3500 mg/day, in an amount of about 200 mg/day to about 3000 mg/day, in an amount of about 225 mg/day to about 2500 mg/day, in an amount of about 250 mg/day to about 2000 mg/day, in an amount of about 275 mg/day to about 1500 mg/day, in an amount of about 100 mg/day, in an amount of about 125 mg/day, in an amount of about 150 mg/day, in an amount of about 175 mg/day, in an amount of about 200 mg/day, in an amount of about 225 mg/day, in an amount of about 250 mg/day, in an amount of about 275 mg/day, in an amount of about 300 mg/day, in an amount of about 325 mg
  • the subject preferably is a warm-blooded animal.
  • the warm-blooded animal is a mammalian species.
  • Exemplary mammalian species include but are not limited to, for example, humans and domestic animals, such as, for example, dogs, cats and horses. Preferred species are humans.
  • the subject is a middle-aged animal, wherein "middle- aged” refers to an age at which the animal reaches approximately half its expected life span. For human, this is considered to be about 45 years or older. In some embodiments, the subject is a senior or an aged animal, which means for human to be of 55 years age or older, preferably 60 years or older.
  • QBA QBA
  • C20-C22 PUFA for use in the improvement of cognitive performance of humans, wherein QBA is used in an amount of 0.2-5000 mg per day, preferably 10-500 mg/day, and wherein the C20-C22 PUFA is used in an amount of 100-4000 mg/day, preferably 200-2000 mg/day.
  • the C20-C22 PUFA preferably comprises DHA in at least 50% of the omega-3-PUFA
  • the DHA is preferably in the form of the ethyl ester or in the form of a tri-glyceride ester;
  • the QBA preferably is in the form of a free fatty acid or salt thereof, or an ethyl ester or glycerol ester, more preferably in the form of a free fatty acid or salt thereof.
  • Neurons from the brain's hippocampus were derived from embryonic day
  • Neurons from the brain's hippocampus were derived from El 7 pups and incubated for 7 days.
  • the cells were pre-treated with QBA for 48 hours and subsequently challenged with glutamate (25 ⁇ ) for 24 hours.
  • the cultures were then stained with propidium iodide, a marker of cell death, and with tetramethylrhodamine ethyl ester (TMRE), a marker for mitochondrial health.
  • TMRE tetramethylrhodamine ethyl ester
  • the fluorescence of each of these markers was then quantitated with a fluorimeter.
  • QBA decreased cell death and increased cell health after the age-related neurodegenerative insult of glutamate toxicity.
  • Neurons from the brain's hippocampus were derived from El 7 pups and incubated for 7 days.
  • the neurons were then pre-treated with QBA for 48 hours and subsequently exposed to a hypoxia ( ⁇ 0.3% (3 ⁇ 4) for 48 hours.
  • the cultures were stained with calcein AM, a marker of live cells, and with ethidium homodimer, a marker for dead cells. The fluorescence of each of these markers was then quantitated with a fluorimeter.
  • Rats were fed QBA and subjected to an elevated plus-maze.
  • the elevated plus-maze was elevated -85 cm above the floor and consisted of two open and two closed arms of the same size (50x10 cm).
  • the closed arms were surrounded by walls 40 cm high, and the arms were constructed of black acrylic slabs that radiated from a central platform (10x10 cm) to form a plus sign.
  • QBA + DHA decreased anxiety in rats similar to QBA alone as measured by the time in the open arms of the elevated plus maze (Table 7).
  • QBA 10-Hydroxy-2-decenoic acid
  • LPS lipopolysaccharide
  • TNFa tumor necrosis factor-a
  • PBMC peripheral blood mononuclear cells
  • Mice fed QBA had a greater percentage increase in body weight than mice fed the control diet with no differences in food consumption.
  • All 10 of the mice fed QBA and 10 of the 15 control mice were subjected to a cell transfer insult wherein the mice were considered to be in a colitis-related disease state.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PCT/US2015/029790 2014-05-08 2015-05-07 Methods and compositions comprising 10-hydroxy-2-decenoic acid Ceased WO2015171960A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2016566933A JP6819957B2 (ja) 2014-05-08 2015-05-07 １０−ヒドロキシ−２−デセン酸を含む方法及び組成物
BR112016026143A BR112016026143A2 (pt) 2014-05-08 2015-05-07 os métodos e composições compreendendo ácido 10-hidroxi-2-decenóico.
KR1020167034149A KR102399290B1 (ko) 2014-05-08 2015-05-07 10-하이드록시-2-데센산을 포함하는 방법 및 조성물
EP15789367.8A EP3139741A4 (en) 2014-05-08 2015-05-07 Methods and compositions comprising 10-hydroxy-2-decenoic acid
CN201580036769.1A CN106470547B (zh) 2014-05-08 2015-05-07 包含10-羟基-2-癸烯酸的方法和组合物
US15/309,470 US10004711B2 (en) 2014-05-08 2015-05-07 Methods and compositions comprising 10-hydroxy-2-decenoic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990283P 2014-05-08 2014-05-08
US61/990,283 2014-05-08

Publications (1)

Publication Number Publication Date
WO2015171960A1 true WO2015171960A1 (en) 2015-11-12

Family

ID=54393026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/029790 Ceased WO2015171960A1 (en) 2014-05-08 2015-05-07 Methods and compositions comprising 10-hydroxy-2-decenoic acid

Country Status (8)

Country Link
US (1) US10004711B2 (enExample)
EP (1) EP3139741A4 (enExample)
JP (1) JP6819957B2 (enExample)
KR (1) KR102399290B1 (enExample)
CN (1) CN106470547B (enExample)
BR (1) BR112016026143A2 (enExample)
TW (1) TWI743022B (enExample)
WO (1) WO2015171960A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094790A (zh) * 2020-11-17 2020-12-18 招远新兴化工有限公司 一种调节肠道菌群的植物乳杆菌lp45活菌制剂及应用
US11197840B2 (en) * 2015-12-04 2021-12-14 Wah Chin BOON Methods of treating or alleviating mental disorders and associated symptoms

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
CN108310026A (zh) * 2018-04-28 2018-07-24 宁夏医科大学 月见草油在改善多囊卵巢综合征慢性炎症方面的应用
JP7240714B2 (ja) * 2019-01-24 2023-03-16 株式会社山田養蜂場本社 γヒドロキシ酪酸受容体結合剤
CN110916088A (zh) * 2019-11-04 2020-03-27 齐鲁工业大学 一种适合炎性肠病人群的全营养特医食品及制备方法
TWI793922B (zh) * 2021-12-14 2023-02-21 彥臣生技藥品股份有限公司 一種用於提升認知能力之組合物及其用途
CN116570582A (zh) * 2023-05-19 2023-08-11 中国药科大学 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用
CN119745857A (zh) * 2024-12-02 2025-04-04 温州医科大学 10-羟基-2-癸烯酸在药物制备中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065212A1 (en) * 2001-06-14 2005-03-24 Nathalie Pineau Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cuteous signs of aging
WO2013003689A2 (en) * 2011-06-30 2013-01-03 Nitromega Corp. Compositions containing nitro fatty acids
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1033843A (en) 1964-05-26 1966-06-22 Eustace Cecil Barton Wright Pharmaceutical composition for treating thermatoid arthritis
GB1145623A (en) 1966-03-09 1969-03-19 Eustace Cecil Barton Wright Pharmaceutical composition
JPH10114652A (ja) 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk 津液改善剤及びそれを含有する経口投与用組成物
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
FR2773484B1 (fr) * 1998-01-09 2001-03-30 Pierre Moreau Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante
DE19844022C1 (de) 1998-09-25 2000-05-25 Sherif Sabry Ragab Mekkawi Verwendung von eisenbindenden Glycoproteinen und/oder 10-Hydroxy-2-decensäure in Verbindung mit Thymochinon zur Behandlung von AIDS
WO2001091575A1 (en) * 2000-06-01 2001-12-06 United Feeds, Inc. Animal food and method
FR2829491B1 (fr) 2001-09-12 2005-09-30 Diverchim Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
JP2005519939A (ja) * 2002-03-08 2005-07-07 モンサント テクノロジー エルエルシー 炎症性疾患の治療および予防
KR20050057127A (ko) 2002-09-06 2005-06-16 하야시바라 겐 정제 로얄 젤리
JP2004131407A (ja) * 2002-10-09 2004-04-30 Yamada Bee Farm ローヤルゼリー又はその水溶性画分を有効成分とする抗うつ性組成物
JP4657778B2 (ja) 2004-03-30 2011-03-23 曽田香料株式会社 アラキドン酸代謝抑制剤
JP4727939B2 (ja) 2004-03-31 2011-07-20 アピ株式会社 低アレルゲン化ローヤルゼリーの製造方法
JP4579620B2 (ja) * 2004-08-25 2010-11-10 アピ株式会社 エストロゲン様作用剤及びその製造方法、並びに骨粗しょう症予防剤及び骨粗しょう症治療剤
CN1836671A (zh) 2005-03-21 2006-09-27 通化盛和药业股份有限公司 一种中药软胶囊及其制备方法和质量控制方法
FR2892410B1 (fr) 2005-10-21 2010-10-15 Fabre Pierre Dermo Cosmetique Nouveaux hydro-acides gras insatures et leur utilisation dermo cosmetologique
CA2632934A1 (en) * 2005-12-20 2007-07-05 Novozymes Biologicals, Inc. Surfactants systems for surface cleaning
CN101370490A (zh) * 2005-12-29 2009-02-18 希尔氏宠物营养品公司 用于预防或治疗炎症性肠病的组合物及其制备方法
WO2007130581A2 (en) 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
JP4749366B2 (ja) 2007-03-23 2011-08-17 株式会社山田養蜂場本社 ローヤルゼリー粉末からなる錠剤およびその製造方法
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
JP2009274961A (ja) 2008-05-12 2009-11-26 Api Co Ltd 吸収促進剤
WO2009154197A1 (ja) * 2008-06-17 2009-12-23 ジャパンローヤルゼリー株式会社 認知障害改善剤
JP2010111646A (ja) * 2008-11-07 2010-05-20 Hayashibara Biochem Lab Inc 潰瘍性大腸炎治療剤
JP2010260833A (ja) * 2009-05-11 2010-11-18 Daicho Kikaku:Kk 抗自己免疫疾患剤
CN101570482B (zh) 2009-06-09 2012-12-26 李应阳 由ω-氯辛醇合成蜂王酸的方法
JP2012031153A (ja) * 2010-06-29 2012-02-16 Takara Bio Inc 脂肪燃焼促進剤
JP5770453B2 (ja) 2010-11-22 2015-08-26 八幡物産株式会社 ローヤルゼリー含有組成物及びソフトカプセル
JP5923699B2 (ja) * 2011-03-30 2016-05-25 アピ株式会社 老化防止剤
CN102408395B (zh) 2011-10-24 2014-04-02 广西师范大学 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
EP2822403B1 (en) * 2012-03-07 2022-05-04 Children's Medical Center Corporation Methods and uses for enhancing, improving, or increasing fertility or reproductive function
CN104427887A (zh) * 2012-03-14 2015-03-18 雅培制药有限公司 包含RRR-α生育酚和多不饱和脂肪酸的营养组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065212A1 (en) * 2001-06-14 2005-03-24 Nathalie Pineau Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cuteous signs of aging
WO2013003689A2 (en) * 2011-06-30 2013-01-03 Nitromega Corp. Compositions containing nitro fatty acids
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Effects of Hydroxydecine (10-hydroxy-2-decenoic acid) on skin barrier structure and function in vitro and clinical efficacy in the treatment of UV-induced xerosis.", EUR J DERMATOL., vol. 21, no. 6, pages 906 - 15, XP008172110 *
See also references of EP3139741A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197840B2 (en) * 2015-12-04 2021-12-14 Wah Chin BOON Methods of treating or alleviating mental disorders and associated symptoms
US20220117925A1 (en) * 2015-12-04 2022-04-21 Wah Chin BOON Methods of treating or alleviating mental disorders and associated symptoms
AU2016364670B2 (en) * 2015-12-04 2022-08-04 Wah Chin Boon Methods of treating or alleviating mental disorders and associated symptoms
CN112094790A (zh) * 2020-11-17 2020-12-18 招远新兴化工有限公司 一种调节肠道菌群的植物乳杆菌lp45活菌制剂及应用
CN112094790B (zh) * 2020-11-17 2021-03-02 河北一然生物科技有限公司 一种调节肠道菌群的植物乳杆菌lp45活菌制剂及应用

Also Published As

Publication number Publication date
US10004711B2 (en) 2018-06-26
CN106470547B (zh) 2020-10-09
EP3139741A1 (en) 2017-03-15
JP6819957B2 (ja) 2021-01-27
KR102399290B1 (ko) 2022-05-17
CN106470547A (zh) 2017-03-01
KR20170003637A (ko) 2017-01-09
BR112016026143A2 (pt) 2018-08-07
US20170181995A1 (en) 2017-06-29
JP2017514874A (ja) 2017-06-08
TW201622717A (zh) 2016-07-01
EP3139741A4 (en) 2017-11-29
TWI743022B (zh) 2021-10-21

Similar Documents

Publication Publication Date Title
US10004711B2 (en) Methods and compositions comprising 10-hydroxy-2-decenoic acid
Romanova et al. Evaluation of the content of polyunsaturated fatty acids in artemia at different stages of ontogenesis
Wu et al. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders
Nayak et al. Dietary supplementation with ω6 LC-PUFA-rich algae modulates zebrafish immune function and improves resistance to streptococcal infection
Balfry et al. Influence of Dietary Lipid Composition on the Immune System and Disease
Delaporte et al. Incorporation and modification of dietary fatty acids in gill polar lipids by two bivalve species Crassostrea gigas and Ruditapes philippinarum
Pottel et al. Omega-3 fatty acids: physiology, biological sources and potential applications in supportive cancer care
JP2014195460A (ja) 乳幼児用調合乳におけるＤＰＡ（ｎ−６）油の使用
Al-Khalaifah et al. Dietary source of polyunsaturated fatty acids influences cell cytotoxicity in broiler chickens
JPH0788301B2 (ja) 記憶喪失の治療または予防用組成物
Nur Mahendra et al. Omega‐6: Its Pharmacology, Effect on the Broiler Production, and Health
Sirri et al. Modifying egg lipids for human health
Mensah Food bioactive compounds–polyunsaturated fatty acids (PUFA): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
US20200009099A1 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
Jeong et al. Lipid and fatty acid composition in Nannochloropsis oculata cultured in varying salinities
AL-KHALAIFAH et al. Fatty Acids and Immune Function
Knoch et al. Study of the effects of dietary polyunsaturated fatty acids: Molecular mechanisms involved in intestinal inflammation
Sartaj et al. Production of Omega‐3 and Omega‐6 PUFA from Food Crops and Fishes
MUANGKEOW Effect of feeding soybean and palm blended oil on laying performance and egg quality
Ouyang et al. Resources and bioactivities of polyunsaturated fatty acids
Al-Khalaifah Lipids as Main Constitutes of Biological Cells
Valérie et al. Natural lipid profile mimicking diets to enhance survival and fitness of restocked salmon parr in river ecosystems?
Thongdet The use of diatoms (Amphora sp.) As immunostimulant in pacific white shrimp (Litopenaeus vannamei) diet
Volker Fat manipulation in the treatment of rheumatoid arthritis: a review
Эргашева et al. OMEGA-3 AND BIOCHEMICAL PROCESSES OF INFLAMMATION IN THE BODY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15789367

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016566933

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15309470

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015789367

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015789367

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167034149

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016026143

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016026143

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161108